anonymous
Guest
anonymous
Guest
The plan is in order for your Xiidra bonus of $1000 to kick in, the OBU has to hit 100%. That plan may or may not happen. The OBU goal was based on a very high first 41/2 month attainment. The OBU reps are 1 against 5 Allergan reps. Allergan is giving a free 3 month to patients to combat the 1 month of Xiidra. Xiidra has no insurance coverage for anyone over 65 and the product is mostly age related. In general the big writers treat mostly geriatric patients. Also, nearly every Xiidra script requires a prior authorization and proof the patient failed on a variety of tears as well as Restasis. There are a lot of factors at play.
The NBU is forced to sample in a market where a sample destroys a script. They sent the NBU all those samples but sent none to the OBU, the OBU understands sampling this market, the NBU doesn't. They are requiring the NBU to call on accounts that the OBU is required to see weekly. This is dry eye, not surgical. The NBU is calling on specialists with no training on a product, the marketplace, or the competitive market, making them look and feel unprepared, unprofessional, and a bit stupid. The OBU reps are battling pharmacies, PAs and Ask Iiris instead of selling. The OBU reps are being forced to present patient profiles to high prescribing writers, a marketing tactic others gave up a decade ago. The OBU reps are fumbling around on iPad presentations instead of having a selling conversation.
And all of us are spending way to much time on web-ex calls, conference calls, training calls, regional calls, point person calls, and webinars.
What's your compensation? Good luck.
This is the MOST accurate post I've read for Shire. You hit every point, without being hateful and using profanity. Whoever you are, I wish you were one of our fearless leaders......as we would have a realistic forecast and expectations.